Welcome to this week’s PharmaSignal Weekly Brief – Global Pharma Roundup. This week, we have seen significant movement in the M&A landscape, with major deals reshaping the biotech and rare disease sectors. Meanwhile, the FDA has been active in granting approvals and fast passes, potentially altering the competitive dynamics in several therapy areas. In the R&D space, promising trial results and strategic funding rounds have made headlines, while policy signals and market trends continue to shape the global pharma landscape. M&A and Strategic Deals BioMarin has acquired Amicus in a $4.8 billion deal, strengthening its rare disease portfolio and expanding…
Author: PharmaSignal News Desk
Cytokinetics FDA approval marks its first drug clearance, challenging Bristol Myers’ Camzyos in the heart drug market.
Merck ADC trial hold affects small cell lung cancer study, with FDA citing higher than anticipated deaths.
BioMarin Amicus acquisition valued at $4.8 billion adds a late-stage asset and two marketed therapies generating $450 million.
Novo Nordisk files for CagriSema approval, competing with Eli Lilly’s obesity drug. Merck and Pfizer succeed in bladder cancer study.
Galapagos TYK2 drug GLPG3667 succeeds in dermatomyositis trial but misses in lupus study, impacting future partnerships.
Moderna H5 influenza vaccine receives undisclosed funding, reviving efforts after losing government support earlier this year.
Lilly obesity pill Orforglipron shows promise in a maintenance trial, potentially broadening its use in obesity treatment.
Insmed drug failure in a study leads to a valuation drop of nearly 20%, affecting its $40 billion market cap.
why-approved-filings-unravel-after-central-teams-disengage